Abstract
Background: Probiotics confer health benefits to the host. However, its clinical effect on irritable bowel syndrome (IBS) is controversial. AIMS: This study was aimed to evaluate the effects of Saccharomyces boulardii on quality of life (QOL) and symptoms in patients with diarrhea-predominant IBS or mixed-type IBS. Methods: Sixty-seven patients with IBS were randomized either to receive S. boulardii at 2×10 live cells as a daily dose (n=34), or placebo (n=33) for 4 weeks. IBS-QOL was assessed at the beginning and end of the treatment phase. IBS-related symptoms, bowel movement frequency, and stool consistency were recorded on a daily basis and assessed each week. Results: The overall improvement in IBS-QOL was higher in S. boulardii group than placebo (15.4% vs 7.0%; P<0.05). All eight domains of IBS-QOL were significantly improved in S. boulardii group; however, placebo group only showed improvements in dysphoria and health worry. Composite scores for IBS symptoms were significantly reduced in both groups to a similar extent. Bowel frequency and stool consistency did not change in either group. Conclusions: S. boulardii improved IBS-QOL better than placebo but was not superior for individual symptoms in patients with diarrhea-predominant IBS or mixed-type IBS.
| Original language | English |
|---|---|
| Pages (from-to) | 679-683 |
| Number of pages | 5 |
| Journal | Journal of Clinical Gastroenterology |
| Volume | 45 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 2011 Sep 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Gastroenterology
Cite this
}
A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome : Effect on quality of Life. / Choi, Chang Hwan; Jo, Sun Young; Park, Hyo Jin; Chang, Sae Kyung; Byeon, Jeong Sik; Myung, Seung Jae.
In: Journal of Clinical Gastroenterology, Vol. 45, No. 8, 01.09.2011, p. 679-683.Research output: Contribution to journal › Article
TY - JOUR
T1 - A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome
T2 - Effect on quality of Life
AU - Choi, Chang Hwan
AU - Jo, Sun Young
AU - Park, Hyo Jin
AU - Chang, Sae Kyung
AU - Byeon, Jeong Sik
AU - Myung, Seung Jae
PY - 2011/9/1
Y1 - 2011/9/1
N2 - Background: Probiotics confer health benefits to the host. However, its clinical effect on irritable bowel syndrome (IBS) is controversial. AIMS: This study was aimed to evaluate the effects of Saccharomyces boulardii on quality of life (QOL) and symptoms in patients with diarrhea-predominant IBS or mixed-type IBS. Methods: Sixty-seven patients with IBS were randomized either to receive S. boulardii at 2×10 live cells as a daily dose (n=34), or placebo (n=33) for 4 weeks. IBS-QOL was assessed at the beginning and end of the treatment phase. IBS-related symptoms, bowel movement frequency, and stool consistency were recorded on a daily basis and assessed each week. Results: The overall improvement in IBS-QOL was higher in S. boulardii group than placebo (15.4% vs 7.0%; P<0.05). All eight domains of IBS-QOL were significantly improved in S. boulardii group; however, placebo group only showed improvements in dysphoria and health worry. Composite scores for IBS symptoms were significantly reduced in both groups to a similar extent. Bowel frequency and stool consistency did not change in either group. Conclusions: S. boulardii improved IBS-QOL better than placebo but was not superior for individual symptoms in patients with diarrhea-predominant IBS or mixed-type IBS.
AB - Background: Probiotics confer health benefits to the host. However, its clinical effect on irritable bowel syndrome (IBS) is controversial. AIMS: This study was aimed to evaluate the effects of Saccharomyces boulardii on quality of life (QOL) and symptoms in patients with diarrhea-predominant IBS or mixed-type IBS. Methods: Sixty-seven patients with IBS were randomized either to receive S. boulardii at 2×10 live cells as a daily dose (n=34), or placebo (n=33) for 4 weeks. IBS-QOL was assessed at the beginning and end of the treatment phase. IBS-related symptoms, bowel movement frequency, and stool consistency were recorded on a daily basis and assessed each week. Results: The overall improvement in IBS-QOL was higher in S. boulardii group than placebo (15.4% vs 7.0%; P<0.05). All eight domains of IBS-QOL were significantly improved in S. boulardii group; however, placebo group only showed improvements in dysphoria and health worry. Composite scores for IBS symptoms were significantly reduced in both groups to a similar extent. Bowel frequency and stool consistency did not change in either group. Conclusions: S. boulardii improved IBS-QOL better than placebo but was not superior for individual symptoms in patients with diarrhea-predominant IBS or mixed-type IBS.
UR - http://www.scopus.com/inward/record.url?scp=80052037138&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052037138&partnerID=8YFLogxK
U2 - 10.1097/MCG.0b013e318204593e
DO - 10.1097/MCG.0b013e318204593e
M3 - Article
C2 - 21301358
AN - SCOPUS:80052037138
VL - 45
SP - 679
EP - 683
JO - Journal of Clinical Gastroenterology
JF - Journal of Clinical Gastroenterology
SN - 0192-0790
IS - 8
ER -